Cargando…

The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma

Multiple myeloma (MM) is a hematological malignancy of plasma cells that produce a monoclonal immunoglobulin protein. Despite significant advances in the treatment of MM, challenges such as resistance to therapy remain. Currently, inhibition of histone deacetylases (HDACs) is emerging as a potential...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Xiaoyang, Xie, Yu, Sun, Xiaoshen, Yao, Yao, Li, Hujun, Li, Zhenyu, Yao, Ruosi, Xu, Kailin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Portland Press Ltd. 2019
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430725/ https://www.ncbi.nlm.nih.gov/pubmed/30782785 http://dx.doi.org/10.1042/BSR20181916

Ejemplares similares

Identification of a novel c-Myc inhibitor with antitumor effects on multiple myeloma cells
por: Yao, Ruosi, et al.
Publicado: (2018)

Oxa Analogues of Nexturastat A Demonstrate Improved HDAC6 Selectivity and Superior Antileukaemia Activity
por: Pflieger, Marc, et al.
Publicado: (2021)

Piperlongumine induces apoptosis and reduces bortezomib resistance by inhibiting STAT3 in multiple myeloma cells
por: Yao, Yao, et al.
Publicado: (2016)

HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma
por: Lee, Sang Wu, et al.
Publicado: (2021)

Identification of a Novel c-Myc Inhibitor 7594-0037 by Structure-Based Virtual Screening and Investigation of Its Anti-Cancer Effect on Multiple Myeloma
por: Yao, Ruosi, et al.
Publicado: (2020)

Anti-Proliferative Activity of HPOB against Multiple Myeloma Cells via p21 Transcriptional Activation
por: Liu, Linlin, et al.
Publicado: (2018)

Indocyanine Green-Nexturastat A-PLGA Nanoparticles Combine Photothermal and Epigenetic Therapy for Melanoma
por: Ledezma, Debbie K., et al.
Publicado: (2020)

CIK Cells and HDAC Inhibitors in Multiple Myeloma
por: Stephan, David, et al.
Publicado: (2017)

Novel dual-targeting c-Myc inhibitor D347-2761 represses myeloma growth via blocking c-Myc/Max heterodimerization and disturbing its stability
por: Yao, Ruosi, et al.
Publicado: (2022)

Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma
por: Li, Hujun, et al.
Publicado: (2022)

Anticancer effect of histone deacetylase inhibitor scriptaid as a single agent for hepatocellular carcinoma
por: Liu, Linlin, et al.
Publicado: (2018)

SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma
por: Heynen, Guus J. J. E., et al.
Publicado: (2022)

HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action
por: Imai, Yoichi, et al.
Publicado: (2019)

Identification of Potential Prognostic Biomarker for Predicting Survival in Multiple Myeloma Using Bioinformatics Analysis and Experiments
por: Zhou, Jian, et al.
Publicado: (2021)

Anti–G Protein–Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial
por: Xia, Jieyun, et al.
Publicado: (2023)

Impact of glucocorticoids on short-term and long-term outcomes in patients with relapsed/refractory multiple myeloma treated with CAR-T therapy
por: Wang, Xue, et al.
Publicado: (2022)

HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma
por: Wang, Xiaoguang, et al.
Publicado: (2020)

Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone
por: Erath, Alexandra, et al.
Publicado: (2020)

Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade
por: Marchini, Antonio, et al.
Publicado: (2016)

Development of Thiazolidinedione-Based HDAC6 Inhibitors to Overcome Methamphetamine Addiction
por: Sharma, Chiranjeev, et al.
Publicado: (2019)

Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma
por: Hirano, Mitsuhito, et al.
Publicado: (2021)

A Novel Hypoxia-Selective Epigenetic Agent RRx-001 Triggers Apoptosis and Overcomes Drug Resistance in Multiple Myeloma Cells
por: Das, Deepika Sharma, et al.
Publicado: (2016)

Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma
por: Uckun, Fatih M.
Publicado: (2021)

Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting
por: Xia, Jieyun, et al.
Publicado: (2023)

Artesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosis
por: Papanikolaou, Xenofon, et al.
Publicado: (2014)

Synergistic interaction between HDAC and MCL-1 inhibitors through downregulation of BCL-XL in multiple myeloma
por: Schneller, Anja, et al.
Publicado: (2021)

Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor
por: Liva, Sophia G, et al.
Publicado: (2020)

HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer
por: Biersack, Bernhard, et al.
Publicado: (2022)

Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
por: Wang, Ying, et al.
Publicado: (2021)

EHMT2 inhibitor BIX-01294 induces endoplasmic reticulum stress mediated apoptosis and autophagy in diffuse large B-cell lymphoma cells
por: Xu, Linyan, et al.
Publicado: (2021)

The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma
por: Tu, Yong-sheng, et al.
Publicado: (2017)

MPT0G413, A Novel HDAC6-Selective Inhibitor, and Bortezomib Synergistically Exert Anti-tumor Activity in Multiple Myeloma Cells
por: Huang, Fang-I, et al.
Publicado: (2019)

Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
por: Thomas, Elizabeth A.
Publicado: (2014)

BIBR1532 inhibits proliferation and enhances apoptosis in multiple myeloma cells by reducing telomerase activity
por: Zhang, Yuefeng, et al.
Publicado: (2023)

Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors
por: Zhang, Pei, et al.
Publicado: (2022)

Rational Targeting of Cdc42 Overcomes Drug Resistance of Multiple Myeloma
por: Nguyen, Phuong, et al.
Publicado: (2019)

A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance
por: Lee, Hee Seung, et al.
Publicado: (2017)

Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma
por: Chen, Ying, et al.
Publicado: (2020)

HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications
por: Harada, Takeshi, et al.
Publicado: (2017)

Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple Myeloma
por: Al-Odat, Omar S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_97is0krejllef54gpdggn67rn7